{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:44:13Z","timestamp":1790685853918,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ygyno.2023.11.021","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:00:11Z","timestamp":1701172811000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Molecular landscape of ERBB2\/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions"],"prefix":"10.1016","volume":"180","author":[{"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lory","family":"Cory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert L.","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.ygyno.2023.11.021_bb0005","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2023.11.021_bb0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-017-4419-x","article-title":"Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature","volume":"166","author":"Petrelli","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.ygyno.2023.11.021_bb0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2023.11.021_bb0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod. Pathol."},{"issue":"22","key":"10.1016\/j.ygyno.2023.11.021_bb0025","article-title":"HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy","volume":"S0090-8258","author":"Klc","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.11.021_bb0030","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-Trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0035","doi-asserted-by":"crossref","unstructured":"M.C. Smithgall, A. Yemelyanova, S. Mathew, S. Gogineni, B. He, T. Zhang, B.D. Robinson, J.J. Tu, HER2\/ERBB2 Immunohistochemical expression and copy number status in ovarian mucinous tumors, Int J Gynecol Pathol. 2023 Jun 30. https:\/\/doi.org\/10.1097\/PGP.0000000000000966. Epub ahead of print.","DOI":"10.1097\/PGP.0000000000000966"},{"issue":"12","key":"10.1016\/j.ygyno.2023.11.021_bb0040","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2023.11.021_bb0045","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ygyno.2023.11.021_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1200\/JCO.2023.41.4_suppl.347","article-title":"Howard a. et al Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)","volume":"41","author":"Elimova","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2023.11.021_bb0055","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0060","article-title":"Pertuzumab plus Trastuzumab in patients with endometrial Cancer with ERBB2\/3 amplification, overexpression, or mutation: results from the TAPUR study","volume":"7","author":"Ahn","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0065","first-page":"JCO2300606","article-title":"Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): a phase 2 basket study","volume":"26","author":"Yoshiaki Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2023.11.021_bb0070","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2023.41.16_suppl.3025","article-title":"Buonocore, et al final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers","volume":"41","author":"Liu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2023.11.021_bb0075","first-page":"7667","article-title":"Efficacy and safety of PI3K\/Akt\/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis","volume":"26","author":"Peng","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.ygyno.2023.11.021_bb0080","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.11.021_bb0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ygyno.2023.11.021_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0095","series-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium, Cancer Discovery","author":"The AACR Project GENIE Consortium","year":"2017"},{"key":"10.1016\/j.ygyno.2023.11.021_bb0100","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2023.11.021_bb0110","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.11.021_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast Cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.11.021_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.11.021_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0130","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.11.021_bb0135","doi-asserted-by":"crossref","first-page":"21762","DOI":"10.1038\/s41598-020-78646-y","article-title":"Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells","volume":"10","author":"Fujimoto","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2023.11.021_bb0140","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2015.63.9161","article-title":"Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3","volume":"34","author":"Andr\u00e9","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.11.021_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in previously treated HER2-low advanced breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10371","key":"10.1016\/j.ygyno.2023.11.021_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet."},{"issue":"15","key":"10.1016\/j.ygyno.2023.11.021_bb0155","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab Deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine Carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2023.11.021_bb0160","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.2022.40.16_suppl.1102","article-title":"A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer","volume":"40","author":"Jiang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2023.11.021_bb0165","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2023.41.16_suppl.2508","article-title":"Phase 1\/2 study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: phase 1 DF1001 monotherapy dose-escalation results","volume":"41","author":"Safran","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.11.021_bb0170","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2023.11.021_bb0175","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ygyno.2023.11.021_bb0180","series-title":"Presented at: American Association for Cancer Research (AACR) 2022 Annual Meeting; April 8-14, New Orleans, LA","article-title":"A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)","author":"Reiss","year":"2022"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823015652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823015652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:54:10Z","timestamp":1715820850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823015652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":36,"alternative-id":["S0090825823015652"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.11.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular landscape of ERBB2\/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}